JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

Benzinga Newsdesk www.benzinga.com Negative 57.3%

Neg 57.3% Neu 0% Pos 0%

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.